Antiviral Therapy

1.2(top 50%)

impact factor

3.3K(top 5%)

papers

72.4K(top 5%)

citations

92(top 5%)

h-index

1.3(top 50%)

impact factor

3.6K

all documents

74.3K

doc citations

127(top 10%)

g-index

Top Articles

#	Title	Journal	Year	Citations
1	Silver Nanoparticles Inhibit Hepatitis B virus Replication	Antiviral Therapy	2008	489
2	Silver nanoparticles inhibit hepatitis B virus replication	Antiviral Therapy	2008	296
3	Challenges of Convalescent Plasma Infusion Therapy in Middle East Respiratory Coronavirus Infection: A Single Centre Experience	Antiviral Therapy	2018	275
4	The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan	Antiviral Therapy	2000	263
5	Human Coronaviruses: What Do They Cause?	Antiviral Therapy	2007	254
6	Response-Guided Therapy: Optimizing Treatment now and in the Future	Antiviral Therapy	2008	250
7	Selection of Hepatitis B Virus Polymerase Mutations in HIV-Coinfected Patients Treated with Tenofovir	Antiviral Therapy	2005	249
8	Long-Term Lamivudine Therapy Reduces the Risk of Long-Term Complications of Chronic Hepatitis B Infection even in Patients without Advanced Disease	Antiviral Therapy	2007	230
9	Susceptibility of HIV-2, Siv and Shiv to Various Anti-HIV-1 Compounds: Implications for Treatment and Postexposure Prophylaxis	Antiviral Therapy	2004	228
10	Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment	Antiviral Therapy	2008	222
11	In vitroSelection and Characterization of HIV-1 with Reduced Susceptibility to PMPA	Antiviral Therapy	1999	214
12	Human coronaviruses: what do they cause?	Antiviral Therapy	2007	200
13	Management of Antiviral Resistance in Patients with Chronic Hepatitis B	Antiviral Therapy	2004	200
14	Chronic Hepatitis C and Genotyping: The Clinical Significance of Determining HCV Genotypes	Antiviral Therapy	2005	199
15	The World Health Organization's global strategy for prevention and assessment of HIV drug resistance	Antiviral Therapy	2008	191
16	Interruption of Antiretroviral Therapy and Risk of Cardiovascular Disease in Persons with HIV-1 Infection: Exploratory Analyses from the SMART Trial	Antiviral Therapy	2008	191
17	Combination Therapy with Lopinavir/Ritonavir, Ribavirin and Interferon-α for Middle East Respiratory Syndrome	Antiviral Therapy	2016	177
18	Prevalence of comedications and effect of potential drug–drug interactions in the Swiss HIV Cohort Study	Antiviral Therapy	2010	172
19	In Vitro Susceptibility of Adefovir-Associated Hepatitis B Virus Polymerase Mutations to other Antiviral Agents	Antiviral Therapy	2007	167
20	Rosiglitazone in the Treatment of Haart-Associated Lipodystrophy – a Randomized Double-Blind Placebo-Controlled Study	Antiviral Therapy	2003	164
21	Indomethacin Has a Potent Antiviral Activity against Sars Coronavirus	Antiviral Therapy	2006	163
22	Hepatitis B surface antigen seroclearance during chronic HBV infection	Antiviral Therapy	2010	162
23	A Sustained Virological Response to Interferon or Interferon/Ribavirin Reduces Hepatocellular Carcinoma and Improves Survival in Chronic Hepatitis C: A Nationwide, Multicentre Study in Taiwan	Antiviral Therapy	2006	162
24	Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods	Antiviral Therapy	2012	161
25	Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D	Antiviral Therapy	2010	158
26	Impact of Neuraminidase Mutations Conferring Influenza Resistance to Neuraminidase Inhibitors in the N1 and N2 Genetic Backgrounds	Antiviral Therapy	2006	155
27	Cross-Resistance Testing of Next-Generation Nucleoside and Nucleotide Analogues against Lamivudine-Resistant HBV	Antiviral Therapy	2005	155
28	Influenza Virus Susceptibility and Resistance to Oseltamivir	Antiviral Therapy	2007	152
29	Some HIV Antiretrovirals Increase Oxidative Stress and Alter Chemokine, Cytokine or Adiponectin Production in Human Adipocytes and Macrophages	Antiviral Therapy	2007	149
30	HBV Genotypes: Relevance to Natural History, Pathogenesis and Treatment of Chronic Hepatitis B	Antiviral Therapy	2011	146
31	Altered Fat Differentiation and Adipocytokine Expression are Inter-Related and Linked to Morphological Changes and Insulin Resistance in HIV-1-Infected Lipodystrophic Patients	Antiviral Therapy	2004	144
32	Safety and Immunogenicity from a Phase I Trial of Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine	Antiviral Therapy	2007	144
33	Depression and Clinical Progression in HIV-Infected Drug Users Treated with Highly Active Antiretroviral Therapy	Antiviral Therapy	2005	140
34	HIV-1 Infection Leads to Increased HLA-E Expression Resulting in Impaired Function of Natural Killer Cells	Antiviral Therapy	2005	140
35	Molecular Genetics of HBV Infection	Antiviral Therapy	2010	139
36	In Vitro Susceptibility of Adenovirus to Antiviral Drugs is Species-Dependent	Antiviral Therapy	2005	139
37	Predicting HIV Coreceptor Usage on the Basis of Genetic and Clinical Covariates	Antiviral Therapy	2007	137
38	Are Adverse Events of Nevirapine and Efavirenz Related to Plasma Concentrations?	Antiviral Therapy	2005	135
39	Intravenous Ribavirin for Hantavirus Pulmonary Syndrome: Safety and Tolerance during 1 Year of Open-Label Experience	Antiviral Therapy	1999	132
40	Prediction of Treatment-Related HBsAg Loss in HBeAg-Negative Chronic Hepatitis B: A Clue from Serum HBsAg Levels	Antiviral Therapy	2007	131
41	HIV Infection and Obesity: Where Did All the Wasting Go?	Antiviral Therapy	2012	130
42	HIV-1 Infection Alters Gene Expression in Adipose Tissue, Which Contributes to HIV-1/Haart-Associated Lipodystrophy	Antiviral Therapy	2006	127
43	The Natural History of Chronic HBV Infection and Geographical Differences	Antiviral Therapy	2010	124
44	The World Health Organization's global strategy for prevention and assessment of HIV drug resistance	Antiviral Therapy	2008	123
45	Natural Polymorphism of the HIV-1 Integrase Gene and Mutations associated with Integrase Inhibitor Resistance	Antiviral Therapy	2007	123
46	A Genotypic Drug Resistance Interpretation Algorithm that Significantly Predicts Therapy Response in HIV-1-Infected Patients	Antiviral Therapy	2002	122
47	Rates of Emergence of HIV Drug Resistance in Resource-Limited Settings: A Systematic Review	Antiviral Therapy	2013	121
48	Amantadine-Oseltamivir Combination therapy for H5N1 Influenza Virus Infection in Mice	Antiviral Therapy	2007	121
49	Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment	Antiviral Therapy	2008	120
50	Low Plasma Concentrations of Indinavir are Related to Virological Treatment Failure in HIV-1-Infected Patients on Indinavir-Containing Triple Therapy	Antiviral Therapy	1998	120

Scientometrics

Overviews

Citing Bodies

Antiviral Therapy

Top Articles